Cardiometabolic Effects of Anti-obesity Pharmacotherapy
Purpose of Review
We review recent studies discussing the impact of pharmacologic agents for weight loss on clinical cardiovascular events, as well as cardiometabolic risk factors.
Pharmacotherapy with current FDA-approved medications for weight loss can significantly improve known risk factors for the development of cardiovascular disease such as hypertension, hyperlipidemia, insulin resistance, inflammatory biomarkers, and the quantity of visceral fat, as well as non-alcoholic fatty liver disease. However, data regarding the actual reduction in clinical cardiovascular events with the use of weight loss medications is scarce.
Pharmacotherapy for weight loss may have additional benefit in optimizing patient’s cardiometabolic comorbidities and improving their clinical cardiovascular outcomes, but each drug should be carefully selected based upon individual patient characteristics.
KeywordsObesity Metabolic syndrome Weight loss medications Heart disease
The authors thank Megin Myers, CRNP, for her critical review of the manuscript.
Compliance with Ethical Standards
Conflict of Interest
NA has consulted for Novo Nordisk. AA has consulted for Novo Nordisk and is a consultant for Andrew Technologies. ARC declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Pollack AA. AMA recognizes obesity as a disease. New York Times. Archived from the original on June. 2013;18.Google Scholar
- 3.Centers for Disease Control and Prevention: Cancers associated with overweight and obesity make up 40 percent of cancers diagnosed in the United States [Press release]. Retrieved from: https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html. (2017).
- 5.•• Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–62. Endocrine Society Guidelines for pharmacotherapy in obesity. CrossRefPubMedGoogle Scholar
- 7.Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.Google Scholar
- 11.Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;(8):CD003641.Google Scholar
- 16.•• Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;2016(375):311–22. Landmark trial demonstrating significant reduction in major cardiovascular outcomes in patients with type 2 diabetes treated with liraglutide. CrossRefGoogle Scholar
- 18.Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.CrossRefPubMedGoogle Scholar
- 21.Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Behavioral modification and lorcaserin for overweight and obesity management (BLOOM) study group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.CrossRefPubMedGoogle Scholar
- 22.Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.• Sahebkar A, Simental-Mendía LE, Reiner Ž, Kovanen PT, Simental-Mendía M, Bianconi V, Pirro M. Effect of orlistat on plasma lipids and body weight: a systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res. 2017. Recent meta-analysis demonstrating optimization of lipid profiles with use of orlistat. Google Scholar
- 32.Alberti KG, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation. Circulation. 2009;120(16):1640–5.CrossRefPubMedGoogle Scholar
- 33.Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427–36.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–52.CrossRefPubMedGoogle Scholar
- 43.Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(s2):1–87.CrossRefPubMedGoogle Scholar
- 44.Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, Schwenke DC, et al. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change. Diabetes Care. 2010;33(11):2297–303.CrossRefPubMedPubMedCentralGoogle Scholar
- 48.Pouliot MC, Després JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73(7):460–8.CrossRefPubMedGoogle Scholar
- 52.•• Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. Trial that demonstrated benefit of liraglutide in reversing NAFLD. CrossRefPubMedGoogle Scholar
- 54.Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;11:2014.Google Scholar
- 55.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;2002(346):393–403.Google Scholar